{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T02:53:18Z","timestamp":1782355998800,"version":"3.54.5"},"reference-count":50,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2024,3,26]],"date-time":"2024-03-26T00:00:00Z","timestamp":1711411200000},"content-version":"unspecified","delay-in-days":25,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Janssen Research & Development, LLC, Spring House, PA"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["RMD Open"],"accepted":{"date-parts":[[2024,2,8]]},"published-print":{"date-parts":[[2024,3]]},"abstract":"<jats:sec>\n                  <jats:title>Objective<\/jats:title>\n                  <jats:p>Evaluate long-term guselkumab effectiveness across Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA)-recognised domains\/related conditions of psoriatic arthritis (PsA).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Post hoc analyses used data from DISCOVER-2 (<jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT03158285\">NCT03158285<\/jats:ext-link>) biologic\/Janus-kinase inhibitor-na\u00efve participants with active PsA (\u22655 swollen\/\u22655 tender joints, C-reactive protein \u22650.6\u2009mg\/dL), randomised (1:1:1) to guselkumab every 4 or 8 weeks (Q4W\/Q8W) or placebo with crossover to guselkumab. Outcomes aligned with key GRAPPA-recognised domains of overall disease activity, peripheral arthritis, axial disease, enthesitis\/dactylitis and skin psoriasis (nail psoriasis was not evaluated). PsA-related conditions (inflammatory bowel disease (IBD)\/uveitis) were assessed via adverse events through W112. Least squares mean changes from baseline through W100 in continuous outcomes employed repeated measures mixed-effects models adjusting for baseline scores. Binary measure response rates were determined with non-responder imputation for missing data.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>442\/493 (90%) of guselkumab-randomised patients completed treatment through W100. Following early reductions in disease activity with guselkumab, durable improvements were observed across key PsA domains (swollen\/tender joints, psoriasis, spinal pain, enthesitis\/dactylitis) through W100. Response rates of therapeutically relevant targets generally increased through W100 with guselkumab Q4W\/Q8W: Disease Activity Index for PsA low disease activity (LDA) 62%\/59%, enthesitis resolution 61%\/70%, dactylitis resolution 72%\/83%, 100% improvement in Psoriasis Area and Severity Index 59%\/53%, Psoriatic Arthritis Disease Activity Score LDA 51%\/49% and minimal disease activity 38%\/40%. Through W112, no cases of IBD developed among guselkumab-randomised patients and one case of uveitis was reported.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>In biologic-na\u00efve patients with active PsA, guselkumab provided early and durable improvements in key GRAPPA-recognised domains through 2 years, with substantial proportions achieving important treatment targets.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/rmdopen-2023-003977","type":"journal-article","created":{"date-parts":[[2024,3,26]],"date-time":"2024-03-26T13:27:49Z","timestamp":1711459669000},"page":"e003977","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":11,"title":["Guselkumab provides durable improvement across psoriatic arthritis disease domains: post hoc analysis of a phase 3, randomised, double-blind, placebo-controlled study"],"prefix":"10.1136","volume":"10","clinical-trial-number":[{"clinical-trial-number":"nct03158285","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03158285","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4756-663X","authenticated-orcid":false,"given":"Laura C","family":"Coates","sequence":"first","affiliation":[{"name":"Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4528-310X","authenticated-orcid":false,"given":"Laure","family":"Gossec","sequence":"additional","affiliation":[{"name":"INSERM, Institut Pierre Louis d'Epid\u00e9miologie et de Sant\u00e9 Publique, Sorbonne Universite, Paris, France"},{"name":"Rheumatology Department, AP-HP, Piti\u00e9-Salp\u00eatri\u00e8re Hospital, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6063-3000","authenticated-orcid":false,"given":"Miriam","family":"Zimmermann","sequence":"additional","affiliation":[{"name":"Immunology, Janssen Medical Affairs, LLC, Zug, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"May","family":"Shawi","sequence":"additional","affiliation":[{"name":"Immunology, Janssen Research & Development LLC, Titusville, New Jersey, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7427-8246","authenticated-orcid":false,"given":"Emmanouil","family":"Rampakakis","sequence":"additional","affiliation":[{"name":"Scientific Affairs, JSS Medical Research Inc, Montreal, Quebec, Canada"},{"name":"McGill University, Montreal, Quebec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalie J","family":"Shiff","sequence":"additional","affiliation":[{"name":"Department of Community Health & Epidemiology, University of Saskatchewan, Saskatoon, Saskatchewan, Canada"},{"name":"Janssen Scientific Affairs, LLC, Horsham, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexa P","family":"Kollmeier","sequence":"additional","affiliation":[{"name":"Janssen Research & Development LLC, San Diego, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xie L","family":"Xu","sequence":"additional","affiliation":[{"name":"Janssen Research & Development LLC, San Diego, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2571-788X","authenticated-orcid":false,"given":"Peter","family":"Nash","sequence":"additional","affiliation":[{"name":"Griffith University, Nathan, Queensland, Australia"},{"name":"The University of Queensland, Brisbane, Queensland, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6620-0457","authenticated-orcid":false,"given":"Philip J","family":"Mease","sequence":"additional","affiliation":[{"name":"Rheumatology Research, Providence Swedish Medical Center, Seattle, Washington, USA"},{"name":"University of Washington, Seattle, Washington, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4155-9105","authenticated-orcid":false,"given":"Philip S","family":"Helliwell","sequence":"additional","affiliation":[{"name":"Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2024,3,26]]},"reference":[{"key":"2025090313401730000_10.1.e003977.1","doi-asserted-by":"crossref","DOI":"10.1016\/j.berh.2021.101670","article-title":"Clinical features of psoriatic arthritis","volume":"35","author":"Kishimoto","year":"2021","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"2025090313401730000_10.1.e003977.2","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/ker365"},{"key":"2025090313401730000_10.1.e003977.3","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.jaad.2023.10.021","article-title":"A clinical review of structural damage in psoriatic arthritis for dermatologists: from pathogenesis to ongoing controversies","volume":"90","author":"Merola","year":"2024","journal-title":"J Am Acad Dermatol"},{"key":"2025090313401730000_10.1.e003977.4","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2013.07.023"},{"key":"2025090313401730000_10.1.e003977.5","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2004.032482"},{"key":"2025090313401730000_10.1.e003977.6","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1038\/s41584-022-00798-0","article-title":"Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA): updated treatment recommendations for psoriatic arthritis 2021","volume":"18","author":"Coates","year":"2022","journal-title":"Nat Rev Rheumatol"},{"key":"2025090313401730000_10.1.e003977.7","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbspin.2023.105534","article-title":"Impact of key manifestations of psoriatic arthritis on patient quality of life, functional status, and work productivity: findings from a real-world study in the United States and Europe","volume":"90","author":"Walsh","year":"2023","journal-title":"Joint Bone Spine"},{"key":"2025090313401730000_10.1.e003977.8","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1002\/art.40726","article-title":"Special article: 2018 American College of Rheumatology\/National Psoriasis Foundation guideline for the treatment of psoriatic arthritis","volume":"71","author":"Singh","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"2025090313401730000_10.1.e003977.9","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-217159"},{"key":"2025090313401730000_10.1.e003977.10","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)30265-8"},{"key":"2025090313401730000_10.1.e003977.11","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)30263-4"},{"key":"2025090313401730000_10.1.e003977.12","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1093\/rheumatology\/keac375","article-title":"Guselkumab provides sustained domain-specific and comprehensive efficacy using composite indices in patients with active psoriatic arthritis","volume":"62","author":"Coates","year":"2023","journal-title":"Rheumatology (Oxford)"},{"key":"2025090313401730000_10.1.e003977.13","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1002\/art.42010","article-title":"Long-term efficacy and safety of guselkumab, a monoclonal antibody specific to the p19 subunit of interleukin-23, through two years: results from a phase III, randomized, double-blind, placebo-controlled study conducted in biologic-naive patients with active psoriatic arthritis","volume":"74","author":"McInnes","year":"2022","journal-title":"Arthritis Rheumatol"},{"key":"2025090313401730000_10.1.e003977.14","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1007\/s40744-022-00443-y","article-title":"Residual disease associated with suboptimal treatment response in patients with psoriatic arthritis: a systematic review of real-world evidence","volume":"9","author":"Coates","year":"2022","journal-title":"Rheumatol Ther"},{"key":"2025090313401730000_10.1.e003977.15","first-page":"2286","article-title":"A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index","volume":"21","author":"Garrett","year":"1994","journal-title":"J Rheumatol"},{"key":"2025090313401730000_10.1.e003977.16","doi-asserted-by":"publisher","DOI":"10.1002\/art.23568"},{"issue":"Suppl 10","key":"2025090313401730000_10.1.e003977.17","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1002\/acr.24242","article-title":"Measuring outcomes in psoriatic arthritis","volume":"72","author":"Ogdie","year":"2020","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2025090313401730000_10.1.e003977.18","doi-asserted-by":"publisher","DOI":"10.1159\/000250839"},{"key":"2025090313401730000_10.1.e003977.19","doi-asserted-by":"publisher","DOI":"10.3109\/09546634.2013.865009"},{"key":"2025090313401730000_10.1.e003977.20","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2009.122259"},{"key":"2025090313401730000_10.1.e003977.21","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2015-207507"},{"key":"2025090313401730000_10.1.e003977.22","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2012-201341"},{"key":"2025090313401730000_10.1.e003977.23","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2008.102053"},{"key":"2025090313401730000_10.1.e003977.24","doi-asserted-by":"crossref","first-page":"e715","DOI":"10.1016\/S2665-9913(21)00105-3","article-title":"Efficacy of guselkumab on axial involvement in patients with active psoriatic arthritis and sacroiliitis: a post-hoc analysis of the phase 3 DISCOVER-1 and DISCOVER-2 studies","volume":"3","author":"Mease","year":"2021","journal-title":"Lancet Rheumatol"},{"key":"2025090313401730000_10.1.e003977.25","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1007\/s40744-023-00592-8","article-title":"Efficacy of guselkumab on axial-related symptoms through up to 2 years in adults with active psoriatic arthritis in the phase 3, randomized, placebo-controlled DISCOVER-2 study","volume":"10","author":"Mease","year":"2023","journal-title":"Rheumatol Ther"},{"key":"2025090313401730000_10.1.e003977.26","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2020-001457","article-title":"Guselkumab, an inhibitor of the IL-23p19 subunit, provides sustained improvement in signs and symptoms of active psoriatic arthritis: 1 year results of a phase III randomised study of patients who were biologic-naive or TNF\u03b1 inhibitor-experienced","volume":"7","author":"Ritchlin","year":"2021","journal-title":"RMD Open"},{"key":"2025090313401730000_10.1.e003977.27","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1002\/art.41553","article-title":"Efficacy and safety of guselkumab, an interleukin-23p19-specific monoclonal antibody, through one year in biologic-naive patients with psoriatic arthritis","volume":"73","author":"McInnes","year":"2021","journal-title":"Arthritis Rheumatol"},{"key":"2025090313401730000_10.1.e003977.28","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1111\/bjd.20568","article-title":"Five-year maintenance of clinical response and health-related quality of life improvements in patients with moderate-to-severe psoriasis treated with guselkumab: results from VOYAGE 1 and VOYAGE 2","volume":"185","author":"Reich","year":"2021","journal-title":"Br J Dermatol"},{"key":"2025090313401730000_10.1.e003977.29","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1093\/rheumatology\/keac500","article-title":"Comparative effectiveness of guselkumab in psoriatic arthritis: updates to a systematic literature review and network meta-analysis","volume":"62","author":"Mease","year":"2023","journal-title":"Rheumatology (Oxford)"},{"key":"2025090313401730000_10.1.e003977.30","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1001\/jamadermatol.2018.0793","article-title":"Efficacy of guselkumab compared with adalimumab and placebo for psoriasis in specific body regions: a secondary analysis of 2 randomized clinical trials","volume":"154","author":"Foley","year":"2018","journal-title":"JAMA Dermatol"},{"key":"2025090313401730000_10.1.e003977.31","doi-asserted-by":"crossref","first-page":"2859","DOI":"10.1007\/s13555-023-01012-z","article-title":"Efficacy of guselkumab in treating nails, scalp, hands, and feet in patients with psoriasis and self-reported psoriatic arthritis","volume":"13","author":"Orbai","year":"2023","journal-title":"Dermatol Ther (Heidelb)"},{"key":"2025090313401730000_10.1.e003977.32","doi-asserted-by":"crossref","first-page":"105469","DOI":"10.1016\/j.jbspin.2022.105469","article-title":"The updated GRAPPA and EULAR recommendations for the management of psoriatic arthritis: similarities and differences","volume":"90","author":"Coates","year":"2023","journal-title":"Joint Bone Spine"},{"key":"2025090313401730000_10.1.e003977.33","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.220928"},{"key":"2025090313401730000_10.1.e003977.34","doi-asserted-by":"crossref","first-page":"855","DOI":"10.36849\/JDD.6216","article-title":"Serious gastrointestinal-related adverse events among psoriasis patients treated with guselkumab in VOYAGE 1 and VOYAGE 2","volume":"20","author":"Foley","year":"2021","journal-title":"J Drugs Dermatol"},{"key":"2025090313401730000_10.1.e003977.35","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1016\/j.jaad.2021.11.004","article-title":"Consistent safety profile with up to 5 years of continuous treatment with guselkumab: pooled analyses from the phase 3 VOYAGE 1 and VOYAGE 2 trials of patients with moderate-to-severe psoriasis","volume":"86","author":"Blauvelt","year":"2022","journal-title":"J Am Acad Dermatol"},{"key":"2025090313401730000_10.1.e003977.36","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/s40264-023-01361-w","article-title":"Long-term safety of guselkumab in patients with psoriatic disease: an integrated analysis of eleven phase II\/III clinical studies in psoriasis and psoriatic arthritis","volume":"47","author":"Strober","year":"2024","journal-title":"Drug Saf"},{"key":"2025090313401730000_10.1.e003977.37","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1111\/jdv.14868","article-title":"Shifting the focus - the primary role of IL-23 in psoriasis and other inflammatory disorders","volume":"32","author":"Gooderham","year":"2018","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2025090313401730000_10.1.e003977.38","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2021-001679","article-title":"Guselkumab induces robust reduction in acute phase proteins and type 17 effector cytokines in active psoriatic arthritis: results from phase 3 trials","volume":"7","author":"Sweet","year":"2021","journal-title":"RMD Open"},{"key":"2025090313401730000_10.1.e003977.39","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1007\/s40744-022-00444-x","article-title":"Collagen turnover biomarkers associate with active psoriatic arthritis and decrease with guselkumab treatment in a phase 3 clinical trial (DISCOVER-2)","volume":"9","author":"Schett","year":"2022","journal-title":"Rheumatol Ther"},{"issue":"Suppl 1","key":"2025090313401730000_10.1.e003977.40","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1136\/annrheumdis-2023-eular.604","article-title":"AB1085\u2005changes in serum cytokines and collagen proteins correlate with durability of guselkumab efficacy and continued disease improvement through 2 years in patients with active psoriatic arthritis","volume":"82","author":"Siebert","year":"2023","journal-title":"Ann Rheum Dis 586"},{"key":"2025090313401730000_10.1.e003977.41","doi-asserted-by":"crossref","unstructured":"Siebert S , Schett G , Raychaudhuri SP , et al . Changes in serum cytokines by week 24 correlate with long-term efficacy of guselkumab through two years in bio-na\u00efve adults with PsA. Arthritis Rheumatol 2022;74 (Suppl 9). Available: https:\/\/acrabstracts.org\/abstract\/changes-in-serum-cytokines-by-week-24-correlate-with-long-term-efficacy-of-guselkumab-through-two-years-in-bio-naive-adults-with-psa\/ [Accessed 20 Feb 2023].","DOI":"10.1136\/annrheumdis-2023-eular.2523"},{"key":"2025090313401730000_10.1.e003977.42","doi-asserted-by":"crossref","unstructured":"McGonagle D , Atreya R , Abreu M , et al . POS1531\u2005guselkumab, an IL-23p19 subunit\u2013specific monoclonal antibody, binds CD64+ myeloid cells and potently neutralises IL-23 produced from the same cells. Ann Rheum Dis 2023:1128\u20139.","DOI":"10.1136\/annrheumdis-2023-eular.826"},{"key":"2025090313401730000_10.1.e003977.43","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1016\/j.jid.2021.01.005","article-title":"Differential changes in inflammatory mononuclear phagocyte and T-cell profiles within psoriatic skin during treatment with guselkumab vs. secukinumab","volume":"141","author":"Mehta","year":"2021","journal-title":"J Invest Dermatol"},{"key":"2025090313401730000_10.1.e003977.44","doi-asserted-by":"crossref","first-page":"464","DOI":"10.3109\/03009742.2015.1020864","article-title":"Up-regulation of CD64-expressing monocytes with impaired Fc\u03b3R function reflects disease activity in polyarticular psoriatic arthritis","volume":"44","author":"Matt","year":"2015","journal-title":"Scand J Rheumatol"},{"key":"2025090313401730000_10.1.e003977.45","doi-asserted-by":"crossref","unstructured":"Eyerich K , Krueger J , Greving C , et al . Differentiation of therapeutic antibodies targeting interleukin (IL)-23. Arthritis Rheumatol 2022;74 (Suppl 9). Available: https:\/\/acrabstracts.org\/abstract\/differentiation-of-therapeutic-antibodies-targeting-interleukin-il-23\/ [Accessed 20 Oct 2023].","DOI":"10.26226\/m.62fa008ef61b200019980eb6"},{"key":"2025090313401730000_10.1.e003977.46","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2022-002195","article-title":"Sustained and improved guselkumab response in patients with active psoriatic arthritis regardless of baseline demographic and disease characteristics: pooled results through week 52 of two phase III, randomised, placebo-controlled studies","volume":"8","author":"Ritchlin","year":"2022","journal-title":"RMD Open"},{"key":"2025090313401730000_10.1.e003977.47","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2021-220991"},{"key":"2025090313401730000_10.1.e003977.48","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1002\/acr2.11523","article-title":"Multidomain efficacy and safety of guselkumab through 1 year in patients with active psoriatic arthritis with and without prior tumor necrosis factor inhibitor experience: analysis of the phase 3, randomized, placebo-controlled DISCOVER-1 study","volume":"5","author":"Ritchlin","year":"2023","journal-title":"ACR Open Rheumatol"},{"key":"2025090313401730000_10.1.e003977.49","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1007\/s40744-023-00582-w","article-title":"Six-month persistence and multi-domain effectiveness of guselkumab in adults with psoriatic arthritis: real-world data from the CorEvitas Psoriatic Arthritis\/Spondyloarthritis Registry","volume":"10","author":"Mease","year":"2023","journal-title":"Rheumatol Ther"},{"key":"2025090313401730000_10.1.e003977.50","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1007\/s40744-022-00518-w","article-title":"PsABIOnd study and eDaily substudy design: long-term effectiveness and safety of guselkumab and IL-17 inhibitors in routine clinical practice in patients with psoriatic arthritis","volume":"10","author":"Siebert","year":"2023","journal-title":"Rheumatol Ther"}],"container-title":["RMD Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/rmdopen-2023-003977","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,3]],"date-time":"2025-09-03T20:40:27Z","timestamp":1756932027000},"score":1,"resource":{"primary":{"URL":"https:\/\/rmdopen.bmj.com\/lookup\/doi\/10.1136\/rmdopen-2023-003977"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3]]},"references-count":50,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,3,26]]},"published-print":{"date-parts":[[2024,3]]}},"alternative-id":["10.1136\/rmdopen-2023-003977"],"URL":"https:\/\/doi.org\/10.1136\/rmdopen-2023-003977","relation":{},"ISSN":["2056-5933"],"issn-type":[{"value":"2056-5933","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3]]}}}